You are here: Industry Insights > Cellect Biotechnology

News List

The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharm firstwordpharma
August 16, 2021
Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission ("SEC") on August 10
Cellect Biotechnology and Washington University finalize accelerated Clinical Trial Agreement biospectrumasia
July 10, 2019
Collaboration Achieves First Significant Milestone with Successful Execution of Technology Transfer
Cellect Biotechnology reports Q1 2019 results biospectrumasia
May 29, 2019
Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.